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Background:  Diabetic retinopathy is a common microvascular complication of diabetes mellitus (DM) and the leading cause of 
blindness in adults. Homocysteine, a risk factor with toxic effects on vascular endothelial cells, and bilirubin, a protectant with 
antioxidant and anti-inflammatory properties on the vasculature, have been reported to be linked to vaso-occlusive disorders. 
Therefore, the author of the present study investigated the association between the levels of plasma homocysteine and serum to-
tal bilirubin and the incidence of diabetic retinopathy as a chronic microvascular complication in patients with type 2 diabetes 
mellitus (T2DM).
Methods:  A total of 102 patients with T2DM who visited our hospital from January 2009 to January 2010 were assessed. 
Results:  Of the 102 patients, the prevalence of diabetic retinopathy was 67 cases (65.7%) according to clinical ophthalmic exam-
ination. The duration of DM (P<0.001), age (P=0.003), fasting blood glucose (P=0.045) and urine albumin-creatinine ratio (P=
0.015) in univariate analysis and plasma homocysteine level (P=0.038), duration of DM (P=0.001), and total bilirubin level (P=
0.012) in multiple logistic regression analysis were statistically significantly associated with the incidence of diabetic retinopathy.
Conclusion:  The present study indicates that homocysteine and bilirubin may be useful biomarkers for increased risk of diabet-
ic retinopathy since retinopathy in patients with T2DM was linked to higher plasma homocysteine level and decreased serum 
total bilirubin level.
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INTRODUCTION
The incidence of diabetes mellitus (DM) and its complications 
are increasing rapidly due to an aging population and the West-
ernization of life styles [1]. Diabetic retinopathy is a common 
microvascular complication that develops in the early period 
of DM and induces visual impairment and even blindness in 
adults. Thus early diagnosis and appropriate treatments are 
important [2]. Diabetic retinopathy is caused primarily by mi-
crovascular injury and the duration of DM, hyperglycemia, 
hypertension, and hyperlipidemia have been shown to be risk 
factors for diabetic retinopathy [3]. Recent studies have report-
ed that homocysteine was linked to vaso-occlusive disorders 
in the eye and the level of plasma homocysteine may be a use-
ful biomarker or a novel risk factor for increased risk of dia-
betic retinopathy in patients with type 2 diabetes mellitus 
(T2DM) [4,5]. Few studies exist on the relationship between 
bilirubin and microvasculopathy, such as diabetic retinopathy. 
However, bilirubin may exhibit strong antioxidant and anti-
inflammatory properties on the vasculature [6,7]. Therefore, 
the authors of the present study suggest that bilirubin may 
have an endogenous protective effect on the retinal vascula-
ture in patients with T2DM.
  In the present study, the association among the level of plas-
ma homocysteine as a risk factor, serum total bilirubin as an 
endogenous protectant and the presence of diabetic retinopa-
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thy as a chronic common complication and peripheral micro-
vascular disorder in patients with T2DM was investigated.
METHODS
Study population
The present study was conducted on 102 patients with T2DM 
who were confirmed with insulin secretion test in the Depart-
ment of Internal Medicine and underwent fundoscopic exam-
inations for the assessment of retinopathy in the Department 
of Ophthalmology in Daegu Medical Center from January 2009 
to January 2010. Patients were excluded from the present study 
if they had a history of chronic alcohol drinking, hepatobiliary 
abnormalities, or any other acute disease. The patients with 
blood levels greater than three times the normal level of ami-
notransferase (AST) or alanine aminotransferase (ALT), or with 
problems in the evaluation of diabetic retinopathy due to oth-
er reasons were excluded. The present study was conducted 
under participant voluntary consent after explanation of the 
purpose, methods, and course.
Study design and assessments
A detailed questionnaire was completed for each of the 102 
participating patients. Information obtained included age, 
gender, smoking history, history of alcohol consumption or 
hepatobiliary disorders, duration of DM, and history of hyper-
tension or cardiovascular diseases. Additionally, height, waist 
circumference, blood pressure, fasting blood glucose (FBG), 
2-hour postprandial blood glucose (2PPBG), C-peptide, and 
insulin levels were obtained. Fasting venous blood was drawn 
on the day of examination via a venipuncture from the patient’s 
antecubital vein and baseline biochemical profiles including 
serum total bilirubin, AST, ALT, glycosylated hemoglobin 
(HbA1c), creatinine, C-reactive protein (CRP) and lipid pro-
files were analyzed using the ARCHITECT c8000 (Toshiba, 
Tokyo, Japan). The standard reference range of total bilirubin 
is 3.4 to 20.5 μmol/L. For plasma homocysteine measurement, 
blood samples were collected in tubes containing EDTA and 
plasma homocysteine concentrations were analyzed using a 
HITACHI 7600 (Hitachi, Tokyo, Japan). The standard reference 
range of plasma homocysteine is 5.0 to 15.0 µmol/L.
  All patients underwent full ophthalmologic examinations 
through dilated pupils including fundus with a binocular indi-
rect ophthalmoscope (Keeler Instruments Inc., Broomall, PA, 
USA) and slit lamp biomicroscope using 90-diopter lens (Carl 
Zeiss, Jena, Germany). Diabetic retinopathy was clinically clas-
sified by an ophthalmologist as cases without diabetic retinop-
athy; proliferative diabetic retinopathy (PDR) with neovascu-
larization, scars, vitreous hemorrhage, or retinal detachment; 
and non-proliferative diabetic retinopathy (NPDR) with in-
creased capillary permeability, capillary obstruction and dis-
tention, microaneurysm formation, cotton wool spots, or hard 
exudate. Non-proliferative retinopathy was divided into mild, 
moderate and severe NPDR. 
Data analysis
Statistical analysis was performed using SPSS version 15.0 (SPSS 
Inc., Chicago, IL, USA) and the baseline characteristics of par-
ticipants were presented as the mean±standard deviation and 
n (%). Data were compared using an independent-sample Stu-
dent’s t-test for continuous data, odds ratio (OR) and chi-square 
test for categorical variables, and the Mann-Whitney U test for 
nonparametric data with an irregular distribution. Multiple 
logistic regression analysis was performed to assess indepen-
dent associations between the presence of key risk factors of 
diabetic retinopathy including statistically significant factors 
in univariate analysis and suggested biomarkers such as plas-
ma homocysteine and total bilirubin levels. A P value less than 
0.05 was considered statistically significant. 
RESULTS
Baseline characteristics
The baseline clinical and laboratory characteristics of the pres-
ent study population are shown in Table 1. Among the partici-
pants, 54 were male and 48 were female, and the mean age was 
59 years. The average duration of DM was 9.3 years. The labo-
ratory data showed a mean HbA1c of 7.9%, FBG of 8.4 mmol/
L, 2PPBG of 13.2 mmol/L, homocysteine of 18.3 µmol/L, and 
total bilirubin of 11.7 µmol/L. 
Clinical characteristics in patients with T2DM according to 
the incidence of retinopathy 
Characteristics of the participants according to the incidence 
of retinopathy are shown in Tables 2 and 3. The number of pa-
tients with diabetic retinopathy was 67 (65.7%; 62 cases of 
NPDR and 5 cases of PDR) and the number of patients with-
out diabetic retinopathy was 35 (34.3%). As expected, the age 
of patients with diabetic retinopathy was significantly higher 
than that of patients without retinopathy (P<0.01) and pa-597
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min-creatinine ratio (ACR) was 4.3 in the retinopathy group 
and 0.7 in the group without retinopathy, with the diabetic 
retinopathy group showing significantly higher values (P<0.01). 
The level of plasma homocysteine in the group with retinopa-
thy was an average of 19.2 µmol/L and it was higher in com-
parison with the average of 16.3 mmol/L in the group without 
retinopathy; however, the difference was not statistically sig-
nificant (P>0.05) (Table 3). There were no significant differ-
ences between the two groups in gender, smoking, body mass 
index, blood pressure, waist to hip ratio, HbA1c, CRP, choles-
terol concentrations, or renal function (Tables 2 and 3). There 
were no significant differences between the two groups in cur-
rent medication except that the number of patients who took 
angiotensin II receptor blockers (ARBs) was higher in the group 
with retinopathy than in the group without retinopathy (49, 
73.1% vs. 18, 51.4%, P<0.05).
Independent risk factors for diabetic retinopathy
To examine the independent associations between the key risk 
factors and the presence of diabetic retinopathy, a multiple lo-
gistic regression analysis was performed with the significant 
variables in univariate analysis including age, DM duration, 
Table 1. Patient baseline clinical and laboratory characteristics 
Parameter
Patients without  
diabetic  
retinopathy (n=35)
Patients with  
diabetic  
retinopathy (n=67)
Age, yr 55±12 62±11
BMI, kg/m
2 25.2±3.9 24.0±3.7
Waist/Hip ratio 0.940±0.017 0.941±0.019
DM duration, yr 2 (0.0-15.0) 10 (0.0-30.0)
Smoking, n (%) 9 (25.7) 23 (34.3)
Hypertension Hx, n (%) 16 (45.7) 37 (55.2)
CVA Hx, n (%) 1 (2.9) 3 (4.5)
SBP, mm Hg 120 (100-160) 127 (110-190)
DBP, mm Hg 80 (60-90) 80 (50-120)
Hemoglobin, g/dL 13.5 (11.7-18.0) 13.1 (8.4-16.1)
HbA1c, % 7.1 (5.6-12.8) 7.4 (5.0-15.6)
FBG, mmol/L 7.5 (4.7-12.9) 7.9 (4.7-17.5)
2PPBG, mmol/L 11.5 (6.8-22.3) 12.6 (6.3-30.9)
C-peptide, mmol/L 1.0 (0.3-3.1) 0.8 (0.4-8.3)
Total cholesterol, mmol/L 4.8 (2.6-6.7) 4.6 (2.8-9.0)
Triglyceride, mmol/L 1.7 (0.6-6.1) 1.5 (0.5-7.1)
HDL-C, mmol/L 1.2 (0.9-2.6) 1.2 (0.5-2.4)
Non-HDL, mmol/L 3.5 (0.9-5.4) 3.4 (1.8-7.7)
AST, IU/L 25.1 (14.0-98.0) 22.0 (11.0-75.0)
ALT, IU/L 32.1 (10.0-84.0) 20.0 (8.0-75.0)
Homocysteine, µmol/L 13.7 (6.0-65.0) 17.1 (7.0-57.3)
Total bilirubin, µmol/L 13.7 (6.8-51.3) 10.3 (3.4-25.7)
CRP, mg/dL 0.1 (0.0-18.8) 0.1 (0.0-18.8)
Urine ACR, µg/mg 0.1 (0.0-5.9) 0.8 (0.0-73.4)
Values are presented as mean±standard deviation or median (min-
max).
BMI, body mass index; DM, diabetes mellitus; CVA, cerebrovascular 
accident; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HbA1c, glycosylated hemoglobin; FBG, fasting blood glucose; 2PPBG, 
2-hour postprandial glucose; HDL-C, high density lipoprotein cho-
lesterol; AST, aminotransferase; ALT, alanine aminotransferase; CRP, 
C-reactive protein; ACR, albumin-creatinine ratio. 
Table 2. Clinical characteristics in type 2 diabetic patients ac-
cording to the incidence of diabetic retinopathy
Parameter
Patients with-
out diabetic 
retinopathy 
(n=35)
Patients with 
diabetic  
retinopathy 
(n=67)
P value
Age, yr 55±12 62±11 0.003
a
Gender
Male 19 (54.3) 35 (52.2) 0.884
b
Female 16 (45.7) 32 (47.8)
DM duration, yr 3.4±4.3 10.5±7.5 0.000
c
BMI, kg/m
2 25.2±3.9 24.0±3.7 0.112
a
Waist/Hip ratio 0.940±0.017 0.941±0.019 0.851
a
Hypertension 16 (45.7) 37 (55.2) 0.361
b
Smoking 9 (25.7)  23 (34.3) 0.373
b
CVA 1 (2.9) 3 (4.5) 1.000
d
SBP, mm Hg 123.7±12.9 127.5±15.1 0.215
a
DBP, mm Hg 76.0±6.5 79.9±10.9 0.059
a
Values are presented as mean±standard deviation or number (%).
DM, diabetes mellitus; BMI, body mass index; CVA, cerebrovascular 
accident; SBP, systolic blood pressure; DBP, diastolic blood pressure.
aIndependent-samples t-test, 
bMann-Whitney test, 
cChi-square test, 
dFisher’s exact test.
tients with diabetic retinopathy had a significantly longer du-
ration of DM, by 7.2 years on average (P<0.01) (Table 2). In 
addition, FBG of the retinopathy group was on average 8.7 
mmol/L, and was significantly higher than the average of 7.7 
mmol/L in the group without retinopathy (P<0.05). Total bili-
rubin was 10.1 µmol/L in the retinopathy group and 15.1 µmol/
L in the group without retinopathy and the retinopathy group 
had significantly lower bilirubin levels (P<0.01). Urine albu-598
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FBG, total bilirubin, and urine ACR, with homocysteine as the 
biomarker as used in previous studies [4,5]. The analysis showed 
that variables independently associated with diabetic retinop-
athy were a longer duration of DM with an OR of 1.2 (95% 
confidence interval [CI], 1.1 to 1.4), homocysteine with an OR 
of 1.1 (95% CI, 1.0 to 1.1), and total bilirubin with an OR of 0.9 
(95% CI, 0.7 to 1.0) (Table 4). 
DISCUSSION
Diabetic retinopathy is a common ophthalmic complication 
that occurs primarily in the microvasculature of the retina and 
has been estimated to account for 5% of all cases of global blind-
ness [8]. Diabetic retinopathy is also known to be common in 
patients with newly diagnosed T2DM [9].
  The change in the retina of patients with DM includes for-
mation of retinal capillary microaneurysms, increased vascu-
lar permeability, vascular occlusion, proliferation of new 
blood vessels, fibrosis of tissues in the surface of the retina and 
optic disk, and the contraction of fibrovascular proliferations 
and the vitreous [10]. Several hypotheses have been tested on 
the cause and pathogenesis of diabetic retinopathy. In non-
proliferative retinopathy, prolonged hyperglycemia may pro-
duce microaneurysms because of the selective decrease of cells 
in the vicinity of the retinal microvasculature and may also in-
duce thickening of the vascular fundus membrane, endothelial 
proliferation, microvascular dilatation due to decreased endo-
thelin-1 synthesis, increased vascular permeability, and vascu-
lar occlusion in microvascular endothelial cells. In addition, 
prolonged hyperglycemia may increase blood flow and viscos-
ity, resulting in an increase of shear stress against the vascular 
wall, as well as injury of the vascular wall, in severe cases, it is 
known to induce macular edema [11]. However, the main 
pathogenesis of proliferative retinopathy is known to be neo-
vascularization caused by several factors including insulin-like 
growth factor released from a retinal ischemic area [11]. 
  Recently, four biochemical pathways including enhanced 
glucose flux through the polyol pathway, increased intracellu-
lar formation of advanced glycation end-products, activation 
of protein kinase C isoforms, and stimulation of the hexos-
amine pathway have been suggested for eye disorders caused 
by hyperglycemia-induced vascular injury in diabetes. These 
pathogenic mechanisms also appear to be associated with su-
peroxide overproduction by the mitochondrial electron trans-
port chain [12].
  A longer duration of diabetes appears to be the main risk 
factor for diabetic retinopathy, and aging, hyperglycemia, hy-
perlipidemia, proteinuria, severe obesity, early onset of diabe-
tes, alcohol drinking, genetic factors, and various hormones 
including growth hormone have been reported as additional 
risk factors for diabetic retinopathy [13-16]. Similarly, the 
present study showed that a longer duration of DM and aging 
in the group with retinopathy were statistically significant risk 
Table 3. Laboratory characteristics in type 2 diabetic patients 
according to the incidence of diabetic retinopathy
Parameter
Patients with-
out diabetic 
retinopathy 
(n=35)
Patients with 
diabetic reti-
nopathy 
(n=67)
P value
a
HbA1c, % 7.5±1.6 8.1±2.2 0.165
C-peptide, mmol/L 1.2±0.7 1.0±1.0 0.547
FBG, mmol/L 7.7±2.0 8.7±2.8 0.045
2PPBG, mmol/L 11.9±4.0 13.7±5.6 0.102
Total cholesterol, mmol/L 4.7±0.9 4.8±1.1 0.808
Triglyceride, mmol/L 2.0±1.2 1.9±1.3 0.831
HDL-C, mmol/L 1.3±0.4 1.3±0.4 0.748
Non-HDL, mmol/L 3.4±0.9 3.5±1.1 0.723
Creatinine, mg/dL 1.0±0.2 1.3±1.2 0.098
CRP, mg/dL 1.2±3.7 0.8±2.6 0.515
Homocysteine, µmol/L 16.3±11.7 19.2±8.4 0.165
Total bilirubin, µmol/L 15.1±8.0 10.1±4.1 0.000
Urine ACR ratio, µg/mg 0.7±1.4 4.3±11.6 0.015
HbA1c, glycosylated hemoglobin; FBG, fasting blood glucose; 2PPBG, 
2-hour postprandial glucose; HDL, high density lipoprotein choles-
terol; CRP, C-reactive protein; ACR, albumin-creatinine ratio. 
aMann-Whitney test.
Table 4. Adjusted odds ratio for associations between key risk 
factors and the incidence of diabetic retinopathy with logistic 
regression model
Adjusted OR 95% CI P value
Age, yr 1.0 1.0-1.1 0.074
DM duration, yr 1.2 1.1-1.4 0.001
FBG, mmol/L 1.3 1.0-1.6 0.067
Homocysteine, µmol/L 1.1 1.0-1.1 0.038
Total bilirubin, µmol/L 0.9 0.7-1.0 0.012
Urine ACR, µg/mg 1.0 0.8-1.3 0.683
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; FBG, 
fasting blood glucose; ACR, albumin-creatinine ratio.599
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factors for diabetic retinopathy in comparison to the group 
without retinopathy (Table 2). In addition, high FBG level and 
high urine ACR appear to be significant risk factors for diabet-
ic retinopathy, and total bilirubin level is inversely associated 
with the incidence of diabetic retinopathy (Table 3). Regarding 
medications, there were more patients taking ARBs in the group 
with retinopathy, which may be due to the medication being 
used as preventative treatment for a relatively high ACR. A 
longer duration of diabetes was statistically significantly asso-
ciated with diabetic retinopathy not only in univariate analysis 
but also in logistic regression analysis, and thus it was also 
confirmed to be an independent risk factor in the present study 
(Tables 2 and 4). 
  Based on the results from the present study, the author sug-
gest that plasma homocysteine and serum total bilirubin can 
be used as biomarkers of diabetic retinopathy. Homocysteine 
is an amino acid containing a sulfur group produced during 
the metabolism of methionine. Dietary methionine is con-
verted to S-adenosyl methionine, and then demethylated to S-
adenosyl homocysteine, which is hydrolyzed to homocysteine 
and adenosine [17]. The level of total plasma homocysteine 
varies widely depending on age, gender, genetics, geographic 
and environmental factors. In particular, homocysteine may 
be increased primarily in hereditary diseases and with defi-
ciencies of folic acid and vitamins B12 and B6, which are re-
quired for homocysteine metabolism [18,19]. Recent studies 
have shown that homocysteine is associated with an increased 
risk of chronic vascular complications of diabetes including 
coronary artery diseases, stroke, and peripheral arterial dis-
eases, and these mechanisms can be explained by direct toxic 
effects on vascular endothelial cells and an indirect effect on 
normal methylation in endothelial cells [17,20]. In particular, 
hyperhomocysteinemia causes toxic effects on vascular endo-
thelial cells directly or indirectly through the impairment of 
vascular endothelial cells, promotion of platelet activation, en-
hanced coagulability, generation of reactive oxygen species 
with cellular toxicity, decreased antioxidant actions, and vas-
cular smooth muscle cell proliferation [19,21-24]. Recent stud-
ies have reported that elevated homocysteine level may be as-
sociated with the onset of retinopathy as a chronic microvas-
cular complication of diabetes [3-5,25]; however, the results 
were not confirmed and the issue remains controversial [17, 
20,26]. In the present study, the levels of plasma homocysteine 
in the group with retinopathy were higher in comparison to 
those in the group without retinopathy in univariate analysis, 
although statistical significance was not shown (Table 3). Ho-
mocysteine level was added to the key factor list in univariate 
analysis for multiple logistic regression analysis since several 
previous studies have reported homocysteine level as a novel 
biomarker of diabetic retinopathy [3,4]. The homocysteine 
level was independently associated with diabetic retinopathy 
with an OR of 1.1 according to multiple logistic regression 
analysis (Table 4). Consequently, homocysteine level may be a 
useful biomarker for increased risk of diabetic retinopathy. 
  Bilirubin is the metabolic end-product of heme degradation 
and is considered a toxic substance with adverse effects such 
as jaundice [27]. However, recent reports have suggested that 
bilirubin may exert anti-atherosclerotic effects through anti-
oxidant actions [7], anti-inflammatory effects on the vascula-
ture [28,29], and cytoprotectant properties [30]. These proper-
ties are explained by the mechanism of bilirubin inhibition of 
inflammatory cytokine-induced endothelial cell expression of 
vascular cell adhesion molecules [28], inhibition of transmi-
gration of monocytes [31], prevention of the oxidation of low 
density lipoprotein [32], inhibition of inflammation and dys-
function of endothelial cells [29], inhibition of proliferation of 
vascular smooth muscles [33], as well as prevention of the for-
mation of thrombi [7,34]. Notably, oxidative stress has been 
implicated in the pathogenesis of microvascular and macro-
vascular complications of diabetes [35]. A direct pathological 
connection of serum bilirubin with microvascular disorders 
has not been fully established. However, higher serum levels of 
bilirubin are inversely associated with the incidence of not only 
macrovascular diseases, such as coronary arterial disease [36-
38], but also peripheral arterial disease through the anti-ath-
erogenic and antioxidant properties of bilirubin [7]. Recently 
published studies have suggested that elevated serum bilirubin 
may provide protection from coronary microvascular dysfunc-
tion and coronary flow reserve impairment by improving mi-
crovascular integrity [39,40]. In the present study, the correla-
tion between levels of serum total bilirubin and diabetic reti-
nopathy as a chronic microvascular complication was investi-
gated. The results showed an inverse association of bilirubin 
level with retinopathy not only in univariate but also multiple 
logistic regression analysis (Tables 3 and 4), which indicates 
that bilirubin may be an important biomarker of diabetic reti-
nopathy as an endogenous protectant from microvascular com-
plications due to antioxidant and anti-inflammatory properties. 
  There were several limitations in the present study. First, ex-
aminations of dietary deficiencies of folic acid and vitamins 600
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involved in homocysteine metabolism were not performed. 
Second, testing for anti-hepatitis C virus or performing an ul-
trasonogram on the hepatobiliary system which may determine 
the bilirubin level, was not conducted in the present study. 
Third, the study was cross-sectional in a small group, and thus 
additional long term prospective studies are needed in a larger 
population. 
  In summary, including homocysteine and bilirubin levels in 
predictions of diabetic retinopathy may be clinically useful 
since retinopathy in patients with T2DM was linked to higher 
plasma homocysteine level and decreased serum total biliru-
bin level in the present study. Additional studies are necessary 
to confirm these results and evaluate related mechanisms.
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